Probiome

What Probiome does

Probiome is a privately held European pharmaceutical company, headquartered in Łódź, Poland, with a secondary office in Warsaw. It operates as a B2B supplier within the EmergoPharm group, developing and supplying OTC finished products in the field of gastroenterology to pharmaceutical companies. The company's core offering is built on QuantaShield™, a proprietary patented microencapsulation platform designed to deliver sodium butyrate precisely to the distal small intestine and colon — a delivery problem that has historically limited the therapeutic efficacy of oral butyrate.

Probiome's portfolio consists of three products: ButiSan® (500mg microencapsulated sodium butyrate capsules with a 60% butyrate ion delivery rate to the large intestine, applied across IBS, IBD, diverticular disease, and post-chemo/radiotherapy enteritis), ButiRect® (a patented medical device for rectal use with sodium butyrate concentration of 0.91 mmol/ml, targeting mucosal regeneration), and Divertix® (enteral capsules combining 300mg sodium butyrate with four clinically proven probiotic strains for symptomatic uncomplicated diverticular disease). The Divertix product has a completed clinical trial demonstrating symptom relief and improved probiotic colonization.

The business model is B2B finished-product supply to pharmaceutical companies seeking to enrich their portfolio with differentiated gastroenterology offerings. Probiome leverages the EmergoPharm group's manufacturing, regulatory, and distribution infrastructure to reach over 50 countries, enabling scale without the capital burden of standalone international distribution. The company has three patent applications pending (P.442463, P.447248, P.446457) covering its formulation and delivery technology.

Name

Probiome

Website

https://probiome.eu

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Probiome is a Poland-based B2B pharmaceutical company that develops and supplies OTC gastroenterology products (sodium butyrate formulations) built on its proprietary QuantaShield™ microencapsulation platform, serving pharmaceutical companies globally through the EmergoPharm group distribution network.

Ownership category

akta.pro rank

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. OTC Finished Pharmaceutical Products: Development and supply of OTC finished products in gastroenterology, including microencapsulated sodium butyrate products (ButiSan®, ButiRect®, Divertix®). Products are sold B2B to pharmaceutical companies to enrich their portfolio.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Probiome develops and supplies OTC finished pharmaceutical products in the field of gastroenterology, built around its proprietary QuantaShield™ microencapsulation technology for sodium butyrate. Its portfolio comprises ButiSan® capsules (500 mg sodium butyrate for IBS, IBD, diverticular disease and post-oncology enteritis), ButiRect® rectal medical device (0.91 mmol/ml butyrate for mucosal regeneration), and Divertix® capsules combining 300 mg sodium butyrate with four probiotic strains for symptomatic uncomplicated diverticular disease. The company sells these B2B to pharmaceutical industry buyers to enrich their gastroenterology portfolios.

Product overview

Probiome is a European pharmaceutical company developing and supplying OTC finished products in gastroenterology, powered by its proprietary QuantaShield™ microencapsulation technology. The portfolio consists of three core products: ButiSan® (microencapsulated sodium butyrate capsules with up to 500mg per capsule and 60% delivery to large intestine), ButiRect® (patented rectal medical device with butyrate concentration up to 0.91 mmol/ml for mucosal regeneration), and Divertix® (enteral capsules combining 300mg sodium butyrate with 4 clinically-proven probiotic strains for diverticular disease management). All products leverage the QuantaShield™ technology platform for targeted distal gut delivery. The company is part of the EmergoPharm group.

Differentiator

Problem solved

Functional benefit

Brands

• ButiSan®: Microencapsulated 500mg sodium butyrate for dietary management in functional bowel diseases, irritable bowel syndrome, acute diarrhea, inflammatory bowel diseases, and diverticular disease.
• ButiRect®
• Divertix®

Products and services

• ButiSan® Microencapsulated 500mg sodium butyrate capsule for dietary management of functional bowel diseases (IBS, constipation, abdominal pain), acute diarrhea, inflammatory bowel diseases, diverticular disease, post-radiotherapy/chemotherapy enteritis, post-GI surgery recovery, microbiota disturbances during/after antibiotic therapy, and nutritional deficiencies. Features patented 3rd generation technology delivering 60% of butyrate ion to the large intestine. Sold B2B to pharmaceutical companies.
• ButiRect® Patented medical device for rectal use containing microencapsulated sodium butyrate at concentrations up to 0.91 mmol/ml. Supports regeneration of rectal mucosa (erosions, injuries, defects), reduces painful defecation symptoms, supports anal canal tissue regeneration after surgery or radiotherapy, and restores physiological functionality of rectal mucosa. Sold B2B to pharmaceutical companies.
• Divertix® Enteral capsules combining 300 mg sodium butyrate with four probiotic strains (Lactobacillus rhamnosus GG 5×10^9 cfu/dose, Lactobacillus plantarum Lp-115 5×10^9 cfu/dose, Lactobacillus reuteri LRE02 1×10^8 cfu/dose, Bifidobacterium infantis B102 1×10^8 cfu/dose) for dietary management of symptomatic uncomplicated diverticular disease (SUDD) and inflammatory bowel diseases. Clinically proven: SUDD symptom relief and improved probiotic strain colonization demonstrated in completed clinical trial. Sold B2B to pharmaceutical companies.
• QuantaShield™ Technology Platform Proprietary patented microencapsulation technology platform that enables targeted delivery of sodium butyrate to the distal small intestine and colon — the first solution capable of delivering butyrate precisely where it is needed. Offered as a base for creating tailor-made microencapsulated sodium butyrate products to enrich pharmaceutical partners' portfolios.

Quantifiable outcome

• 60% of butyrate ion delivered into large intestine (101.2mg from one capsule vs competitors at 26.9-55.8mg)
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• EmergoPharm GroupcoreStrategic or Co-development PartnerProbiome is a part of EmergoPharm group, leveraging the group's established pharmaceutical manufacturing and distribution infrastructure. EmergoPharm enables Probiome to supply finished OTC products to over 50 countries in the global market, providing manufacturing scale, regulatory expertise, and international distribution reach that would be difficult to build independently.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Capsugel (Lonza): Global capsule and encapsulation technology provider serving pharma and nutraceutical customers. Comparable to Probiome's microencapsulation capability, but as an enabler/CDMO rather than a finished-product brand.
• Evonik: Specialty chemicals company with EUDRAGUARD® and other advanced delivery/coating technologies for pharma and nutraceutical applications. Adjacent to QuantaShield™ microencapsulation as an enabling technology supplier.
• Ferring Pharmaceuticals: Swiss specialty pharma with leading gastroenterology and microbiome-related products (including a stake in microbiome-focused MetaboGen). Overlaps with Probiome's gastroenterology/microbiome focus at the established-pharma tier.
• Chr. Hansen (Novonesis): Global microbial fermentation powerhouse supplying probiotic cultures, enzymes and bioprotective ingredients to food, supplement and pharma industries. Overlaps with Probiome's microbial/probiotic supply, but at vastly greater scale and across many categories.
• IFF Health & Biosciences (DuPont Nutrition): Major ingredient supplier offering probiotic strains, cultures and encapsulation technologies for nutraceutical and pharmaceutical customers. Comparable on probiotic and microencapsulation capabilities, though much broader in portfolio.
• Alfasigma: European specialty pharma company with a significant gastroenterology franchise (e.g., rifaximin-based products). Comparable to Probiome as a European gastro-focused pharma player, though at much larger scale and with prescription products.

Direct peers

• BioGaia: Swedish probiotic company selling clinically-documented Lactobacillus reuteri strains and finished products through partners in pharma and consumer health. Directly comparable on the probiotic-strain-and-B2B-finished-product axis.
• Winclove Probiotics: Dutch developer of proprietary probiotic formulations sold B2B to pharma and supplement brands, with documented clinical studies. Closely matches Probiome's B2B probiotic plus finished-formulation positioning with a clinical-evidence moat.
• Lallemand Health Solutions: Business unit of Lallemand specializing in probiotic formulation, manufacturing and B2B supply for human health and pharma applications. Mirrors Probiome's B2B finished-product supply model within microbiome/gut health.
• Probi AB: Swedish B2B supplier of clinically-documented probiotic strains and finished formulations to consumer-health and pharma partners. Closely comparable to Probiome's B2B probiotic/finished-product model, particularly for Divertix® which pairs butyrate with probiotic strains.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/probiometherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Probiome